Phone: 385 (0)1 17 46 66
Summary: In 689 breast cancer patients in longitudinal study the
concentrations of tumor markers CA 15-3, CEA, CA M26 and CA M29 along with
estrogen and progestin receptors were determined. In 53 patients suffering
from ovarial carcinoma and in 36 patients with endometrial cancer the
concentration of tumor marker CA 125 along with estrogen and progestin
receptors were determined. In breast cancer patients without the evidence
of metastasis (disease free interval) tumor markers were mostly normal.
The ability to detect advanced disease in an order of decreasing
sensitivity was CA 15-3 > CEA > CA M29 > CA M26 (0.61, 0.53, 0.51, 0.47,
respectively). Markers CA M26 and CA M29 combined together exhibit lower
sensitivity (0.71) than CA 15-3 and CEA (0.79), but this was accomplished
with better specificity. All markers varied in accordance with the obvious
disease status changes in greater or lesser extent. Estrogen and progestin
receptor concentrations in endometrial tissue samples were the highest in
hyperplastically altered tissue and the lowest in carcinomatous tissue.
Results suggest strong hormonal activity in precancerous tissue. In
patients with ovarial cancer marker CA 125 have shown very good
concordance with the disease progression or regression.
Research goals: In this study we will determine concentrations of
various parameters such as estrogen and progestin receptors, and tumor
markers CEA, CA 15-3, CA M26, CA M29, CA 125 and osteocalcin in patients
who suffer from breast, ovary and endometrial carcinoma. Determining the
presence and concentration of receptors in tumor tissues we hope to have
the answer to the question if these parameters could be connected with
disease-free interval. Also, we want to know the relationship between
disease-free interval and tumor marker levels. A multiple marker breast
cancer panel will be used to monitor patients in the longitudinal study.
The data will show the relationship between tumor marker levels and disease
progression, regression or stability. Other information about the project.